Biocartis inks deal with Bristol-Myers Squibb for IdyllaTM MSI testing
Category: #health  By Paroma Bhattacharya  Date: 2019-03-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biocartis inks deal with Bristol-Myers Squibb for IdyllaTM MSI testing

Biocartis Group, a molecular diagnostics company based in Belgium, has reportedly signed a collaboration deal with the American pharmaceutical company, Bristol-Myers Squibb, for the IdyllaTM MSI testing with immune-oncology therapies and the potential registration as a companion diagnostic.

Sources revealed that MSI (Microsatellite Instability) is an outcome of the body’s DNA MMR (mismatch repair) system getting inactivated. As a result, spontaneous errors occurring during the normal DNA replication process are not rectified further and eventually lead to tumor growth. Sources added that MSI-High status is found in different tumor types, including around 15 percent of CRC (colorectal) tumors. MSI is also considered an independent factor, possibly predicting a patient’s response to specific immunotherapies.

Herman Verrelst, CEO, Biocartis, commented on the latest move, saying that the company’s association with Bristol-Myers Squibb, which is a frontrunner in the field of immune-oncology therapies, is quite an achievement. He believes that MSI testing can be made accessible to a growing number of patients, given the benefits of the company’s IdyllaTM MSI test. He also added that a wider patient population can benefit from immunotherapies, which will make Biocartis turn personalized medicine into an everyday reality.

As per a press release issued by Biocartis, the entirely-automated IdyllaTM MSI test has received the CE-IVD grading on the 28th of February 2019. It gives information regarding the MSI status 6, 7, 8 of CRC tumors from just a piece of FFPE9 tumor tissue in about 150 minutes. The report added that the collaboration agreement includes joint developments as well as the MSI test registrations for uses in several indications, geographies and commercial settings. Moreover, the prime focus will be on the test’s registration in the United States as a companion diagnostic in metastatic colorectal cancer (mCRC).

For the record, Opdivo (nivolumab), along with low-dose Yervoy (ipilimumab), is the first-ever immune-oncology combination treatment of Bristol-Myers Squibb, that is U.S. FDA-approved for MSI-High or dMMR (mismatch repair deficient) mCRC, which has advanced the treatment with specific chemotherapies.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

FamilyMart to end Chinese joint venture partnership with Ting Hsin
FamilyMart to end Chinese joint venture partnership with Ting Hsin
By Paroma Bhattacharya

Ting Hsin operates overs 2,500 FamilyMart stores in China, sharing revenues and paying royalties to the Japanese firm.

Japan-based convenience store operator, Famil...

FDA and IBT seemingly in agreement on Phase III study design
FDA and IBT seemingly in agreement on Phase III study design
By Paroma Bhattacharya

The US Food and Drug Administration (FDA) has reportedly informed Infant Bacterial Therapeutics (IBT) in writing that the company has responded reasonably to its comments pertaining to the Phase III study design and th...

Kohl’s expresses interest in the acquisition of At Home décor chain
Kohl’s expresses interest in the acquisition of At Home décor chain
By Paroma Bhattacharya

At Home has been exploring a sale, for the last 3 months and has already advanced in a deal negotiation with private equity firms, including Hellman and Friedman.

The largest U.S. department store chain operator Kohl&rsquo...